FOXO4-DRI
A cell-killing anti-aging peptide that clears worn-out 'zombie' cells. One famous mouse study, zero human data, nothing you can feel.
What it is
FOXO4-DRI is built to kill senescent cells, the damaged cells that stop dividing but refuse to die and leak inflammation into the tissue around them. In a 2017 mouse study it restored fur, fitness and kidney function in old and chemo-damaged animals. Nobody has given it to a person in a trial, so you are paying for a mouse result and an idea.
The people running FOXO4-DRI are longevity hobbyists who have already done the cheaper senolytic protocols (fasting, fisetin, the dasatinib-plus-quercetin pulses) and want the peptide version they read about. A few are post-chemo and chasing the chemo-damage arm of the mouse study. Almost none are beginners, and it should stay that way: it is one of the few peptides here whose mechanism is deliberately killing cells.
What you will notice: nothing you can trust. There is no sensation to clearing senescent cells, and there is no blood test you can order that tells you whether it happened. Some people report a day or two of fatigue, soreness or a low-grade off feeling after dosing, which is consistent with cells dying and being cleaned up, and also consistent with injecting anything. The mice got their fur back and ran further on a treadmill. You will not get a readout like that.
The tiers here are pulses: 1, 2.5 or 5 mg subQ every other day for three doses, then 4 to 8 weeks off before you decide on another block. The gap is the point, not a tolerance reset: it is a hit-and-run, one short burst to clear old cells, then weeks for the body to clean up. That mirrors the mice, which got a handful of injections spaced over about a week, not daily shots for months. Start with the 1 mg pulse, run it as the only new thing, and keep a simple log of energy, joint pain and sleep. A 10 mg vial covers three 1 mg blocks or one 2.5 mg block, and a 5 mg block takes 15 mg, a vial and a half. The mistake is turning an expensive pulse into a daily habit.
Evidence sits at animal 2, human 0. The 2017 Cell paper is real and striking: a designed peptide that blocks FOXO4 from holding p53 inside senescent cells, so p53 goes to the mitochondria and triggers those cells' self-destruct while healthy cells are spared. Follow-up lab work looked at cartilage cells, aged testosterone-producing cells and fibrosis. It is good science and it is all mice and dishes. No human dose, no half-life, no safety data, no idea what happens when you clear senescent cells from a wound that is using them to heal.
If you want a longevity peptide with any human footing, SS-31 is in human trials under the name elamipretide, and NAD+ at least has human tolerability data behind it. If what you want is senolysis specifically, the dasatinib-plus-quercetin pulse has small human studies, and it and fisetin cost far less by comparison. FOXO4-DRI is the one to try last, with a clean cancer history, no healing wound, and clear eyes about the fact that you are the trial.
What people use it for
Rejuvenation in old mice
Early daysThe foundational 2017 study showed FOXO4-DRI killed senescent cells selectively and restored fur density, running endurance and kidney function in naturally aged mice and in mice damaged by chemotherapy. It is the single most-cited result in peptide senolytics. It is also the only kind of result that exists: mouse.
Joints and cartilage
Early daysA 2021 lab study tested it on human cartilage cells in a dish and reported clearance of senescent chondrocytes, the cells that drive osteoarthritis. People with worn knees read this as a joint treatment. It is a dish, not a knee, and nobody has injected it into a human joint.
Testosterone with age
Early daysAn aged-mouse study reported that clearing senescent Leydig cells improved testosterone output. Interesting if you are a mouse. In men, low testosterone is diagnosed and treated on labs with tools that have human data; this is not one of them.
Safety in people
Early daysThere is none. No human pharmacokinetics, no half-life, no dose-finding, no long-term follow-up. The mechanism touches p53, the body's main tumor suppressor, and senescent cells are part of normal wound healing, so the two open questions are cancer biology and healing, and nobody has asked them in a person.
How people use it
Safety, in brief
Things people sometimes notice
- A day or two of fatigue or feeling run-down after dosing
- Muscle or joint soreness around dosing days
- Redness or a small lump at the injection site
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice